WASHINGTON, June 30 (Reuters) - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
4.0 times pro forma EBITDA from an estimated 3.6 times at the end of 2013 in order to fund its purchase of Forest Laboratories FRX "> FRX . As such, we downgraded our credit rating for Actavis to BBB from BBB+. Mallinckrodt MNK "> MNK
June 23 (Reuters) - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for...
is still beating the market overall. The fund's best-performing stock during the first quarter of 2014 was Forest Laboratories FRX, which was up 54% during the period following a $25 billion takeover bid from Actavis ACT. The stock was
driven largely by the integration of Warner Chilcott, and earnings have mostly tracked our forecast. Assuming the Forest Laboratories deal closes near the middle of this year, we still think Actavis will post more than $12.5 billion in revenue for
Investor interest in recent tax-advantaged deals has been undeniable. As we saw in Actavis’ acquisition of Forest Laboratories , both the acquirer’s and the acquisition target’s stocks rose after the deal announcement as investors
value estimate for Actavis to $200 per share from $168 after incorporating potential synergies from the announced Forest Laboratories acquisition. As long as management can achieve its $1 billion cost synergy target, the deal should push annual free cash
aligned with shareholders. At Forest Laboratories , for example, the new CEO put ..... Ireland. Likewise, Actavis and Forest Laboratories were up 17% and 39%, respectively ..... February it would acquire Forest Laboratories . The secular trends favoring
been put to to work for shareholders returning hundreds of millions of dollars per year in additional earnings. Forest Laboratories is a pharmaceutical company focused on in-licensing drugs for development. The company's portfolio includes
May 23 (Reuters) - Forest Laboratories Inc said on Thursday that Howard Solomon, who has led the biotech firm since 1977, will retire as chief executive officer at the end of this year and the...